PERISCOPE

What does the score look like?

The homepage describes a clinical decision support system that returns a 7-day and a 30-day risk, a risk category and the top contributing factors, and adds "You decide what action to take." The models are XGBoost, trained per hospital on pre- and intra-operative EHR data. According to the vendor, each hospital's model is recalibrated locally and checked for accuracy across 16 subgroups such as sex and age.

Implementation takes "typically 8 to 12 weeks, depending on your EHR system," and the page says PERISCOPE "integrates directly into your electronic health record interface" without naming an EHR.

Which certificates and clearances does it hold?

Besides the CE mark, the homepage lists ISO 13485 and ISO 27001 and does not name the notified body. The FDA 510(k) database has no record under Healthplus.ai, and funding coverage presents FDA clearance as a goal for the money raised.

How strong is the one published study?

The one PubMed-indexed paper is van der Meijden and colleagues in the Lancet Regional Health Europe, 2025 (PMID 39720095). It covers 253,010 procedures with 23,903 infections within 30 days at three hospitals in the Netherlands and Belgium. After model updating, the 30-day AUROC was 0.82, 0.82 and 0.91 on the 2022 to 2023 temporal validation. The design was retrospective and it evaluates prediction accuracy without testing any change in infection outcomes. Two of the authors work at Healthplus.ai B.V.

The homepage carries testimonials from Deventer Ziekenhuis and Amsterdam UMC and describes the tool as "validated and implemented at leading medical centers of excellence," without a count.

Who funds it, and what does it cost?

Funding coverage lists an undisclosed round from LUMO Labs meant for CE certification and clinical trials, and a EUR 2.3 million late-seed round led by Elevating Capital with LUMO Labs, ROM InWest, PATHENA and Leistone, aimed at the European rollout, a US launch and FDA clearance. A news post on the vendor's site adds BVP and Noso Capital as investors in a seed extension, with no amount. The homepage gives no founding year or founders.

Healthplus.ai gives no price. The homepage links a "Calculate your ROI" tool instead.

The verdict

The published case for PERISCOPE is one retrospective study with 30-day AUROCs of 0.82, 0.82 and 0.91 at three hospitals in the Netherlands and Belgium, and no outcome trial. A surgical service in those countries has the closest match to that data. A US hospital has no FDA clearance to cite, since the vendor claims none.